Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vidya Perera

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Clinical and Translational Science|September 24, 2021
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Joseph Luettgen, et al.
Clinical Pharmacology and Therapeutics|July 19, 2023
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 PhenotypeManting Chiang, Caroline Sychterz, Vidya Perera, et al.
Journal of Clinical Pharmacology|June 28, 2023
Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic ModelManting Chiang, Caroline Sychterz, Lu Gaohua, et al.
Clinical Pharmacokinetics|July 29, 2022
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal ImpairmentVidya Perera, Grigor Abelian, Danshi Li, et al.
Clinical Pharmacokinetics|March 9, 2022
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy ParticipantsVidya Perera, Grigor Abelian, Danshi Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 3, 2013
A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activityVidya Perera, Annette S Gross, Alan Forrest, et al.
Australasian Journal on Ageing|December 3, 2009
The assessment of frailty in older people in acute careSarah N Hilmer, Vidya Perera, Sarah Mitchell, et al.
Cardiology and Therapy|May 31, 2022
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa InhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
Metabolites|October 27, 2022
Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21Caroline Sychterz, Iain Gardner, Manting Chiang, et al.
Scientific Reports|December 23, 2022
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Clinical and Translational Science|September 24, 2021
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Joseph Luettgen, et al.
Clinical Pharmacology and Therapeutics|July 19, 2023
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 PhenotypeManting Chiang, Caroline Sychterz, Vidya Perera, et al.
Journal of Clinical Pharmacology|June 28, 2023
Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic ModelManting Chiang, Caroline Sychterz, Lu Gaohua, et al.
Clinical Pharmacokinetics|July 29, 2022
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal ImpairmentVidya Perera, Grigor Abelian, Danshi Li, et al.
Clinical Pharmacokinetics|March 9, 2022
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy ParticipantsVidya Perera, Grigor Abelian, Danshi Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 3, 2013
A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activityVidya Perera, Annette S Gross, Alan Forrest, et al.
Australasian Journal on Ageing|December 3, 2009
The assessment of frailty in older people in acute careSarah N Hilmer, Vidya Perera, Sarah Mitchell, et al.
Cardiology and Therapy|May 31, 2022
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa InhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
Metabolites|October 27, 2022
Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21Caroline Sychterz, Iain Gardner, Manting Chiang, et al.
Scientific Reports|December 23, 2022
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitorVidya Perera, Zhaoqing Wang, Susan Lubin, et al.
Pageof 5